secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001493152-26-013080
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx appoints Ramtin Agah, MD as Executive Chairman; $450K salary + bonus
-----------------------------------------------------------------------------

- Ramtin Agah, MD appointed Executive Chairman effective Feb 27, 2026; continues as Chief Medical Officer.
- $450,000 annual base salary, discretionary bonus up to 40% of base (first bonus payable in 2027 for 2026).
- Eligible for annual grants of stock options and other equity awards under Company's 2021 Omnibus Equity Incentive Plan.
- Employment at-will; prior consulting agreement replaced; existing Change in Control and Severance Agreement remains in effect.
- CEO Shaun Bagai remains principal executive officer; Dr. Agah reports directly to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315226013080/0001493152-26-013080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315226013080/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer